CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Precigen Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Precigen Inc
20374 SENECA MEADOWS PARKWAY
Phone: (301) 556-9900p:301 556-9900 GERMANTOWN, MD  20876  United States Ticker: PGENPGEN
Business Summary
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Randal J.Kirk 70 1/2/2020 2/1/2008
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc. HelenSabzevari 62 6/1/2020 12/1/2017
Chief Financial Officer HarryThomasian 62 10/18/2021 10/18/2021
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
OKANAGAN SPECIALTY FRUITS INC. 12033 LOOMER ROAD SUMMERLAND CAN
INTREXON ACTOBIOTICS NV INDUSTRIEPARK ZWIJNAARDE 7 C BUILDING D ZWIJNAARDE BEL
Neugenesis Corporation 849 Mitten Road Burlingame CA United States
7 additional Subsidiary records available in full report.

Business Names
Business Name
ActoBio Laboratories Belgium BVBA
Actogenix
Exemplar Genetics, LLC
5 additional Business Names available in full report.

General Information
Number of Employees: 202 (As of 12/31/2023)
Outstanding Shares: 292,869,097 (As of 10/31/2024)
Shareholders: 312
Stock Exchange: NASD
Federal Tax Id: 260084895
Email Address: info@intrexon.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024